Skip to main content
. Author manuscript; available in PMC: 2011 Jul 27.
Published in final edited form as: Biochemistry. 2010 Jul 27;49(29):6177–6183. doi: 10.1021/bi100775t

Figure 4.

Figure 4

Western Blot analysis of endogenous PARP-1 binding to cDDP-G*G* (A) and NoPt (B). The samples were resolved on 8% SDS-PAGE and detected using a PARP-1 antibody. Amount of CFE used: Lanes 1, 4, 7 and 10 in both (A) and (B), 60 μL; Lanes 2, 5, 8 and 11 in both (A) and (B), 15 μL; Lanes 3, 6, 9 and 12 in both (A) and (B), 5 μL; (C) Quantification of the gels. Lanes: a, unactivated PARP-1 binding to cDDP-G*G* (Lane 2 in Figure 4A); b, activated PARP-1 binding to cDDP-G*G* (Lane 8 in Figure 4A); c, unactivated PARP-1 binding to NoPt (Lane 2 in Figure 4B); d, activated PARP-1 binding to NoPt (Lane 8 in Figure 4B).